Exelixis, Inc. (NASDAQ:EXEL) Caught In The Tri-Polar Fight For Domination In Prostate Cancer Treatment

936

Dallas, Texas 04/14/2014 (FINANCIALSTRENDS) –  Exelixis, Inc. (NASDAQ:EXEL) is currently in the midst of one of its lean phases as the studies on one of its most promising drugs –  Comet 1, Phase III – which it proposes to use for treating prostate cancer which is already in metastatic stage, does not appear to be very positive.

The results of the Comet-1 study have not been negative either. But the results and their significance thus far, are inconclusive or appear not to satisfy requirements.

Competitor products for this category include – Johnson & Johnson’s Zytiga, second is Medivation’sXtandi and the third is Bayer’s Xofigo.

Exelixis, Inc. (NASDAQ:EXEL) has already ensured that cabozantinib is approved for medullary thyroid cancer, in the brand name – Cometriq. However, the fact that the market size for this drug is marginal, which is $250million, in comparison to the $1 billion plus sale it can see if the drug is approved for prostate cancer.

Exelixis, Inc. (NASDAQ:EXEL) is in trouble with the lack of same efficacy factors for its drug in comparison to the positive efficacy of the triumvirate.

Exelixis, Inc. (NASDAQ:EXEL) has a market capital of 655.85million. The company has a trading price range per day in the region of $3.35 to $3.59. The 52 week trading high for this cancer drug maker is at $8.1, while the 52 week low is $3.35. In the previous trading session, the drug maker opened trade at $3.51, closing session nearly 0.19 lesser, indicating overall drop by -5.34%.

Exelixis, Inc. (NASDAQ:EXEL) has outstanding shares in the current market at 194.61million. Beta was 2.28. EPS is negative a 1.33. The cancer drug maker will continue to the analysis study on its current favourite drug, cabozantinib, in the hope that it too will soon be able to deliver the current standards of efficacy for cancer drugs, which is in the range of extension of live by 3 to 5 months.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.